Dapivirine News and Research

RSS

Dapivirine is an experimental non-nucleoside reverse transcriptase inhibitor. A gel formulation of dapivirine is now being investigated as a vaginal microbicide.

Vaginal ring and oral PrEP found to be safe for HIV prevention among pregnant cisgender women

The monthly dapivirine vaginal ring and daily oral pre-exposure prophylaxis (PrEP) with tenofovir disoproxil fumarate and emtricitabine were each found to be safe for HIV prevention among cisgender women who started using one of them in their second trimester of pregnancy, according to findings presented today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024

New early phase study evaluates “on-demand” HIV prevention method for women

A fast-dissolving vaginal insert that women would use at or around the time of sex as an "on-demand" HIV prevention method is being evaluated in a new early phase study being conducted by MATRIX, a United States Agency for International Development (USAID)-funded project focused on the early research and development of innovative HIV prevention products for women.

7 Dec 2023

Grand Challenges Canada funding supports market introduction of dapivirine vaginal ring in Southern and East Africa

IPM South Africa NPC, an affiliate of the Population Council, has been issued a 15-month Transition to Scale Phase 2 award from Grand Challenges Canada to support the market introduction of the dapivirine vaginal ring (DapiRing) for women in Southern and East Africa.

16 Nov 2023

Study launched to test a vaginal film that slowly dissolves over the course of 30 days

A vaginal film designed to slowly dissolve over the course of 30 days is being put to the test for the first time in a study launched this week that aims to determine its feasibility and acceptability as a potential HIV prevention method for women.

2 Nov 2023

Use of dapivirine vaginal ring during third trimester of pregnancy poses no safety concerns

A vaginal ring containing the antiretroviral drug dapivirine posed no safety concerns when used in the third trimester of pregnancy, according to results to date from the first study of the dapivirine ring during pregnancy and one of only a few studies of an HIV prevention product in pregnant cisgender women.

20 Feb 2023

WHO recommends the use of first long-acting option to protect women from HIV

The first long-acting option to protect women from HIV, proven to reduce women's HIV risk, has been recommended for use by the World Health Organization.

1 Dec 2021

Study: Adolescent girls and young women can and will use HIV prevention products with consistency

Adolescent girls and young women can and will use HIV prevention products with consistency, according to interim results of a study of two different methods: daily use of the antiretroviral (ARV) tablet Truvada as oral pre-exposure prophylaxis (PrEP) and the monthly dapivirine vaginal ring, a new HIV prevention product currently under regulatory review in several countries.

15 Jul 2021

Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference

Researchers seeking to develop on-demand and behaviorally congruent HIV prevention options for people who practice anal sex are reporting the results of three early phase clinical trials of rectal microbicides at this week's HIV Research for Prevention (HIV R4P) Virtual Conference.

3 Feb 2021

WHO recommends dapivirine vaginal ring as additional HIV prevention choice for at-risk women

WHO today recommended that the dapivirine vaginal ring (DPV-VR) may be offered as an additional prevention choice for women at substantial risk of HIV infection as part of combination prevention approaches.

1 Feb 2021

IPM announces WHO's prequalification of dapivirine ring to reduce women’s HIV risk

The nonprofit International Partnership for Microbicides is pleased to announce the World Health Organization's prequalification of the dapivirine ring, a monthly vaginal ring to reduce women's HIV risk.

30 Nov 2020

Researchers launch study to evaluate safety of HIV prevention methods in breastfeeding women

The development of safe and effective HIV prevention methods for cisgender women has long been a global health priority, yet research in women during pregnancy and breastfeeding, when they are most vulnerable to infection, has lagged years behind.

31 Aug 2020

Monthly vaginal ring for HIV prevention receives positive opinion from EMA

The International Partnership for Microbicides today welcomed a positive opinion from the European Medicines Agency on the dapivirine vaginal ring for use by cisgender women ages 18 and older in developing countries to reduce their risk of HIV-1 infection.

24 Jul 2020

Monthly vaginal ring moves one step closer to becoming a new HIV prevention method

A vaginal ring intended to be used for a month at a time has moved one step closer to potentially becoming a new HIV prevention method for cisgender women in sub-Saharan Africa, who despite being the face of the epidemic, have few options for protecting themselves against getting infected.

24 Jul 2020

Study to evaluate safety of PrEP and dapivirine ring in pregnant women

A woman who is eight-months pregnant is the first participant to be enrolled into a study evaluating the safety and acceptability of two different HIV prevention approaches when used during pregnancy -- the monthly dapivirine vaginal ring, which is currently under regulatory review, and a daily antiretroviral (ARV) pill called Truvada, an approach already approved in several countries and commonly referred to as PrEP, short for pre-exposure prophylaxis.

10 Feb 2020

Dapivirine News and Research

Vaginal ring and oral PrEP found to be safe for HIV prevention among pregnant cisgender women

New early phase study evaluates “on-demand” HIV prevention method for women

Grand Challenges Canada funding supports market introduction of dapivirine vaginal ring in Southern and East Africa

Study launched to test a vaginal film that slowly dissolves over the course of 30 days

Use of dapivirine vaginal ring during third trimester of pregnancy poses no safety concerns

WHO recommends the use of first long-acting option to protect women from HIV

Study: Adolescent girls and young women can and will use HIV prevention products with consistency

Researchers report trial results of rectal microbicides at HIV R4P Virtual Conference

WHO recommends dapivirine vaginal ring as additional HIV prevention choice for at-risk women

IPM announces WHO's prequalification of dapivirine ring to reduce women’s HIV risk

Researchers launch study to evaluate safety of HIV prevention methods in breastfeeding women

Monthly vaginal ring for HIV prevention receives positive opinion from EMA

Monthly vaginal ring moves one step closer to becoming a new HIV prevention method

Study to evaluate safety of PrEP and dapivirine ring in pregnant women

New clinical trial to examine the safety of dapivirine vaginal ring and PrEP in pregnant women

Vaginal ring used by most women for HIV prevention in open-label study

New clinical trial aims to examine safety and use of two HIV prevention tools

MTN launches new study to empower teen girls with choices in HIV prevention

IPM begins first clinical trial of vaginal rings to prevent HIV in women

NIH-supported first HIV vaccine efficacy study begins in South Africa

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News